Approach to fever in the neutropenic host

  • Athena Stoupis
  • Stephen H. Zinner
Part of the Cancer Treatment and Research book series (CTAR)


The approach to fever in the neutropenic host in large part depends on an understanding of the basic immune defect. White blood cells are critically important in maintaining an infection-free state. Nearly 30 years ago, the risk of serious bacterial infections in patients with a low number of circulating leukocytes was first recognized by Bodey and coworkers [1]. Diminished polymorphonuclear leukocyte numbers or function and impaired humoral immunity result in the development of serious infections, with the attendant risk of morbidity and mortality.


Febrile Neutropenia Neutropenic Patient Empiric Antibiotic Therapy Persistent Fever Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–340.PubMedGoogle Scholar
  2. 2.
    Lee JW, Pizzo PA. Management of the cancer patient with fever and prolonged neutropenia. Hematol Oncol Clin North Am 1993;7:937–960.Google Scholar
  3. 3.
    Pizzo PA, Commers JR, Cotton D, et al. Approaching the controversies in the antibacterial management of cancer patients. Am J Med 1984;76:436–439.PubMedGoogle Scholar
  4. 4.
    Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1989;80(Suppl. 5C):13–20.Google Scholar
  5. 5.
    Pizzo PA, Robichaud KJ, Gill FA, Witebsky PG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101–111.PubMedGoogle Scholar
  6. 6.
    Desser RK, Ultman JE. Risk of severe infection in patients with Hodgkin’s disease or lymphoma after diagnostic laparotomy and splenectomy. Ann Intern Med 1972;77:143–146.PubMedGoogle Scholar
  7. 7.
    Mayer KH, Opal SM. Antibacterial therapy in patients with malignancies. Cancer Metastas Rev 1987;5:271–293.Google Scholar
  8. 8.
    Siber GR, Weitzman SA, Aisenberg AC, et al. Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin’s disease. N Engl J Med 1978;299:442–448.PubMedGoogle Scholar
  9. 9.
    Lamb D, Pilney F, Kelly WD, Good RA. A comparative study of the incidence of anergy with carcinoma, leukemia, Hodgkin’s disease and other lymphomas. J Immunol 1962;89:555–558.PubMedGoogle Scholar
  10. 10.
    Zinner SH. Treatment and prevention of infection in immunocompromised hosts. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia: W.B. Saunders, 1992, pp. 1057–1064.Google Scholar
  11. 11.
    Buchanan GR. Approach to treatment of the febrile cancer patient with low risk neutropenia. Hematol Oncol Clin North Am 1993;7:919–935.Google Scholar
  12. 12.
    Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology 1996;10:599–612.PubMedGoogle Scholar
  13. 13.
    Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low risk subgroup at presentation. Arch Intern Med 1988;148:2561–2568.PubMedGoogle Scholar
  14. 14.
    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992:10:316–322.PubMedGoogle Scholar
  15. 15.
    Pappo AS, Buchanan GR. Predictors of bacteremia in febrile neutropenic children with cancer (abstr.). Proc Annu Meet Am Soc Clin Oncol 1991;10:A1167.Google Scholar
  16. 16.
    Patrick CC. Coagulase-negative staphylococci: Pathogens with increasing clinical significance. J Pediatr 1990;116:497–507.PubMedGoogle Scholar
  17. 17.
    Rubin M, Hathorn JW, Marshall D, et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30–35.PubMedGoogle Scholar
  18. 18.
    Anaissie EJ, Vadhan-Raj S. Is it time to redefine the management of febrile neutropenia in cancer patients? Am J Med 1995:98:224–231.Google Scholar
  19. 19.
    Klastersky J. Febrile neutropenia. Support Care Cancer 1993:1:233–239.PubMedGoogle Scholar
  20. 20.
    Zinner SH, Gaya H, Glauser M, et al. The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983;l:597–603.Google Scholar
  21. 21.
    Giamarellou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. Med Clin North Am 1995:79:559–580.PubMedGoogle Scholar
  22. 22.
    Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Disease, 4th edi. New York: Churchill Livingstone, 1995, pp. 2675–2686.Google Scholar
  23. 23.
    Sickles EA, Greene WH, Wiernick PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715–719.PubMedGoogle Scholar
  24. 24.
    Rubin RH, Green R. Clinical approach to the compromised host with fever and pulmonary infiltrates. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. New York: Plenum, 1994, pp. 121–161.Google Scholar
  25. 25.
    Cockerill FR III, Wilson WR, Carpenter HA, et al. Open lung biopsy in immuno-compromised patients. Arch Intern Med 1985;145:1398–1404.PubMedGoogle Scholar
  26. 26.
    Cheson BD, Samlowski WE, Tang TT, Spruance SL. Value of open lung biopsy in 87 immunocompromised patients with pulmonary infiltrates. Cancer 1985;55:453–459.PubMedGoogle Scholar
  27. 27.
    Peterson DE, Minah GE, Overholser CD, et al. Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol 1987;5:1461–1468.PubMedGoogle Scholar
  28. 28.
    Gerard M, Defresne N, Daneau D, et al. Incidence and significance of Clostridium difficile in hospitalized cancer patients. Eur J Clin Microbiol Infect Dis 1988;7:274–278.PubMedGoogle Scholar
  29. 29.
    Milligan DW, Kelly JK. Pseudomembranous colitis in a leukemia unit: A report of fatal cases. J Clin Pathol 1979:32:1237–1243.PubMedGoogle Scholar
  30. 30.
    Varki AP, Armitage JO, Feagler JR. Typhlitis in acute leukemia: Successful treatment by early surgical intervention. Cancer 1979;43:695–697.PubMedGoogle Scholar
  31. 31.
    Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992;14(Suppl. 1):S43–S53.PubMedGoogle Scholar
  32. 32.
    Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985:145:1621–1629.PubMedGoogle Scholar
  33. 33.
    Hiemenz J, Skelton J, Pizzo PA. Perspective on the management of catheter-related infections in cancer patients. Pediatr Infect Dis 1986;5:6–11.PubMedGoogle Scholar
  34. 34.
    Johnson PR, Decker MD, Edwards KM, et al. Frequency of broviac catheter infections in pediatric oncology patients. J Infect Dis 1986:154:570–578.PubMedGoogle Scholar
  35. 35.
    Kramer BS, Pizzo PA, Robichaud KJ, et al. Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med 1982;72:561–568.PubMedGoogle Scholar
  36. 36.
    The International Antimicrobial Therapy Cooperative of the European Organization for Research and Treatment of Cancer (Writing Committee: Calandra T, Zinner SH, Viscoli C, de Bock R, Gaya H, Meunier F, Klastersky J, Glauser M). Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Int Med 1993;119:584–593.Google Scholar
  37. 37.
    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 1992;14:1201–1207.PubMedGoogle Scholar
  38. 38.
    Handwerger S, Horowitz H, Coburn K, Kolokathis A, Wormser GP. Infection due to Leuconostoc species: Six cases and review. Rev Infect Dis 1990;12:602–610.PubMedGoogle Scholar
  39. 39.
    Swartz MN. Cellulitis and subcutaneous tissue infections. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Disease, 4th ed. New York: Churchill Livingstone, 1995. pp. 909–929.Google Scholar
  40. 40.
    Zinner SH. New and unusual infections in neutropenic patients. In: Klastersky J, ed. Infectious Complications of Cancer. Boston: Kluwer Academic, 1995, pp. 173–184.Google Scholar
  41. 41.
    Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine 1988;67:77–83.PubMedGoogle Scholar
  42. 42.
    Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994;28(Suppl. 1):7–15.PubMedGoogle Scholar
  43. 43.
    Raad I, Hachera R. Treatment of central venous catheter-related fungemia due to Fusarium oxysporum. Clin Infect Dis 1995:20:709–711.PubMedGoogle Scholar
  44. 44.
    Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995;9:823–847.Google Scholar
  45. 45.
    Samonis G, Bafaloukos D. Fungal infections in cancer patients: An escalating problem [review]. In Vivo 1992:6:183–193.Google Scholar
  46. 46.
    Gokaslan A, Anaissie E. A novel murine model of disseminated trichosporonosis. Infect Immun 1992:60:3339–3344.PubMedGoogle Scholar
  47. 47.
    Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061–1065.PubMedGoogle Scholar
  48. 48.
    Gibson J, Johnson L, Snowdon L, et al. Trends in bacterial infections in febrile neutropenic patients: 1986-1992. Aust N Z j Med 1994:24:374–377.PubMedGoogle Scholar
  49. 49.
    Cometta A, Zinner S, de Bock R, et al. and the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39:445–452.Google Scholar
  50. 50.
    Fergie JE, Shema SJ, Lott L. Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: Analysis of factors associated with a poor outcome. Clin Infect Dis 1994:18:390–394.PubMedGoogle Scholar
  51. 51.
    Schimpff SC, Greene WH, Young VM, et al. Significance of Pseudomonas aeruginosa in the patient with leukemia and lymphoma. J Infect Dis 1974;130(Suppl.):S24–S31.PubMedGoogle Scholar
  52. 52.
    Hersch EM, Bodey GP, Nies BE, Freireich EJ. Causes of death in acute leukemia. JAMA 1965:193:105–109.Google Scholar
  53. 53.
    Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988;6:167–184.PubMedGoogle Scholar
  54. 54.
    Klastersky J, Zinner SH. Synergistic combination of antibiotics in gram-negative bacillary infections. Rev Infect Dis 1982;4:294–298.PubMedGoogle Scholar
  55. 55.
    Klastersky J, Schimpff SC, Gaya H, Glauser MP, Zinner SH. EORTC International Antimicrobial Therapy Cooperative Group. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986:29:263–270.PubMedGoogle Scholar
  56. 56.
    Tattersall MH, Spiers ASD, Darreil JH. Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropenia. Lancet 1972; 1:162–165.PubMedGoogle Scholar
  57. 57.
    Zinner SH, Gaya H, Glauser M, Klastersky J, Schimpff SC, Tattersall MHN. EORTC International Antimicrobial Therapy Cooperative Group. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983;l:597–603.Google Scholar
  58. 58.
    Calandra T, Klasterksy J, Gaya H, Glauser MP, Meunier F, Zinner SH. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692–1698.Google Scholar
  59. 59.
    Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: A randomised trial. Int J Hematol 1993;58:63–72.PubMedGoogle Scholar
  60. 60.
    Martino P, Girmenia C, Raccah R, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 1992;49:49–52.PubMedGoogle Scholar
  61. 61.
    Gutmann L, Williamson R, Kitzis M, et al. Synergism and antagonism in double beta-lactam antibiotic combinations. Am J Med 1986;80(Suppl. 5C):21–29.PubMedGoogle Scholar
  62. 62.
    Joshi JH, Newman KA, Brown BW, et al. Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Support Care Cancer 1993;1:186–194.PubMedGoogle Scholar
  63. 63.
    Young LS. Double beta-lactam therapy in the immunocompromised host. J Antimicrob Chemother 1985;16:4–6.PubMedGoogle Scholar
  64. 64.
    Pizzo PA, Thaler M, Hathorn J, et al. New beta-lactam antibiotics in granulocytopenic patients: New options and new questions. Am J Med 1985;79(Suppl. 2A):75–82.PubMedGoogle Scholar
  65. 65.
    De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP for The Interncontinental Antimicrobial Study Group. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 1994;120:834–844.PubMedGoogle Scholar
  66. 66.
    Bizette GA, Brooks BJ Jr., Alvarez S. Ceftazidime as monotherapy for fever and neutropenia: Experience in a community hospital. J La State Med Soc 1994;146:448–452.PubMedGoogle Scholar
  67. 67.
    Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552–558.PubMedGoogle Scholar
  68. 68.
    Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis. J Infect Dis 1991;164:907–916.PubMedGoogle Scholar
  69. 69.
    Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992;36:1991–1996.PubMedGoogle Scholar
  70. 70.
    Eggimann P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993;32(Suppl. B):151–163.PubMedGoogle Scholar
  71. 71.
    Leyland MJ, Bayston KF, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843–854.PubMedGoogle Scholar
  72. 72.
    Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283–291.PubMedGoogle Scholar
  73. 73.
    Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13:165–176.PubMedGoogle Scholar
  74. 74.
    Donnelly JP, Horrevorts AM, Sauerwein RW, De Pauw BE. High-dose meropenem in meningitis due to Pseudomonas aeruginosa [letter]. Lancet 1992;339:1117.PubMedGoogle Scholar
  75. 75.
    The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185–200.Google Scholar
  76. 76.
    Cometta A, Calandra T, Gaya H, et al. and the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and The Gruppo Italiano Malattie Ematologiche Maligne Dell’Adulto Infection Program. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108–1115.PubMedGoogle Scholar
  77. 77.
    Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, Glauser M (EORTC-IATCG). Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 1991;35:873–878.PubMedGoogle Scholar
  78. 78.
    Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995;20:907–912.PubMedGoogle Scholar
  79. 79.
    Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107–114.PubMedGoogle Scholar
  80. 80.
    Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 1990;8:1998–2004.PubMedGoogle Scholar
  81. 81.
    Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640–3646.PubMedGoogle Scholar
  82. 82.
    Rolston K, Rubenstein EB, Elting LS, et al. Ambulatory management of febrile episodes in low-risk neutropenic patients — an acceptable alternative to hospital based therapy. In: Program Proceedings and Abstracts of the 6th International Symposium Supportive Care in Cancer, 1994.Google Scholar
  83. 83.
    Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995;98:224–231.PubMedGoogle Scholar
  84. 84.
    Gillis S, Dann EL, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hemtaol 1996;51:26–31.Google Scholar
  85. 85.
    De Marie S, Van den Broek PJ, Willemze R, Van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 1993;12:897–906.PubMedGoogle Scholar
  86. 86.
    EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada Clinical Trials Group. (Writing Committee: Calandra T, Zinner SH, Glauser MP, Meunier F, Viscoli C, Feld R, Gaya H, and Klastersky J.) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951–958.Google Scholar
  87. 87.
    Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized propsective study. Antimicrob Agents Chemother 1992;36:1062–1067.PubMedGoogle Scholar
  88. 88.
    EORTC International Antimicrobial Therapy Cooperative Group. (Writing Committee: Meunier F, Gaya H, Calandra T, Glauser M, Klastersky J, Sylvester R, and Zinner S.) Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668–672.Google Scholar
  89. 88a.
    Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexpected fever. Clin Infect Dis 1997;551–573.Google Scholar
  90. 89.
    Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. In: Mandell G, Douglas RG. Bennett JE, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995, pp. 2686–2696.Google Scholar
  91. 90.
    Anttila VJ, Ruutu P, Bondestam S, et al. Hepatosplenic yeast infection in patients with acute leukemia: A diagnostic problem. Clin Infect Dis 1994;18:979–981.PubMedGoogle Scholar
  92. 91.
    Anaissie E, Pinczowski H. Invasive candidiasis during granulocytopenia. Recent Results Cancer Res 1993;132:137–145.PubMedGoogle Scholar
  93. 92.
    Flannery MT, Simmons DB, Saba H, Altus P, Wallach PM, Adelman HM. Fluconazole in the treatment of hepatosplenic candidiasis. Arch Int Med 1992;152:406–408.Google Scholar
  94. 93.
    De Pauw BE, Raemaekers JM, Donnelly JD, Kullberg BJ, Meis JF. An open study on the safety and efficacy of fiuconazole in the treatment of disseminated Candida infections in patients treated for hematologic malignancy. Ann Hematol 1995;70:83–87.PubMedGoogle Scholar
  95. 94.
    Van’t Wout JW, Novakova I, Verhagen CA, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: A randomised comparative study with amphotericin B. J Infect 1991;22:45–52.Google Scholar
  96. 95.
    De Marie S, Janknegt R, Bakker-Woudenberg IA. Clinical use of liposomal and lipid-complexed amphotericin B [review]. J Antimicrob Chemother 1994;33:907–916.PubMedGoogle Scholar
  97. 96.
    Janknegt R, De Marie S, Bakker-Woudenberg IA. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1992;23:279–291.PubMedGoogle Scholar
  98. 97.
    Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994; 14(Suppl. 5):S3–S7.PubMedGoogle Scholar
  99. 98.
    Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533–2536.PubMedGoogle Scholar
  100. 99.
    Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979;67:194–200.PubMedGoogle Scholar
  101. 100.
    Young LS. Neutropenia: Antibiotic combinations for empiric therapy. Eur J Clin Microbiol Infect Dis 1989;8:118–122.PubMedGoogle Scholar
  102. 101.
    Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988;318:1414–1422.PubMedGoogle Scholar
  103. 102.
    Dibenedetto SP, Ragusa R, Ippolito AM, et al. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: A randomized clinical trial. Eur J Haematol 1995;55:93–96.PubMedGoogle Scholar
  104. 103.
    Stone RM, Berg DT, George SL, et al., for The Cancer and Leukemia Group B. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671–1677.PubMedGoogle Scholar
  105. 104.
    Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492–501.PubMedGoogle Scholar
  106. 105.
    American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: Evidence based, clinical practice guidelines [special article]. J Clin Oncol 1994;12:2471–2508.Google Scholar
  107. 106.
    Roilides E, Pizzo PA. Perspectives on the use of cytokines in the management of infectious complications of cancer. Clin Infect Dis 1993;17(Suppl. 2):S385–S389.PubMedGoogle Scholar
  108. 107.
    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323–1332.PubMedGoogle Scholar
  109. 108.
    Ziegler EJ, Fisher CJ Jr., Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429–436.PubMedGoogle Scholar
  110. 109.
    Greenman RI, Schein RMH, Martin MA, et al. and The Xoma Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991:266:1097–1102.Google Scholar
  111. 110.
    Abraham E, Wunderink R, Silverman H, et al. for The TNF-α MAb Sepsis Study Group. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934–941.Google Scholar
  112. 111.
    DinarelJo CA. Blocking interleukin-1 receptors. Int J Clin Lab Res 1994;24:61–79.Google Scholar
  113. 112.
    Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167–227.PubMedGoogle Scholar
  114. 113.
    Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 1995;15:77–105.PubMedGoogle Scholar
  115. 114.
    Winston DJ, Ho WG, Bartani K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 1993:12:283–288.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Athena Stoupis
  • Stephen H. Zinner

There are no affiliations available

Personalised recommendations